Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens

被引：42

作者：

Burman, William J. ^{[1
]}

Cotton, Mark F. ^{[2
]}

Gibb, Diana M. ^{[3
]}

Walker, A. Sarah ^{[3
]}

Vernon, Andrew A. ^{[4
]}

Donald, Peter R. ^{[2
]}

机构：

[1] Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA

[2] Univ Stellenbosch, Fac Hlth Sci, Dept Pediat & Child Hlth, ZA-7505 Tygerberg, Western Cape, South Africa

[3] MRC, Clin Trials Unit, London, England

[4] Ctr Dis Control & Prevent, Atlanta, GA USA

来源：

PLOS MEDICINE | 2008年 / 5卷 / 08期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1371/journal.pmed.0050176

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We are on the threshold of revolutionary improvements in the treatment of tuberculosis. Within five to ten years, it is likely that highly effective three-month regimens will be available to treat both active and latent drug-susceptible tuberculosis. New drug classes that have the potential to dramatically improve the treatment of multidrug-resistant tuberculosis are entering clinical trials. Children have the same right as adults to benefit from research with these new treatments. By making a deliberate choice to avoid the path of least resistance, we can ensure that both adults and children benefit from these advances in tuberculosis treatment.

引用

页码：1168 / 1172

页数：5

共 41 条

[31] Antimycobacterial pyrroles:: Synthesis, anti-Mycobacterium tuberculosis activity and QSAR studies
Ragno, R
Marshall, GR
Di Santo, R
Costi, R
Massa, S
Rompei, R
Artico, M
[J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2000, 8 (06) : 1423 - 1432
[32] Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model
Rosenthal, Ian M.
Zhang, Ming
Williams, Kathy N.
Peloquin, Charles A.
Tyagi, Sandeep
Vernon, Andrew A.
Bishai, William R.
Chaisson, Richard E.
Grosset, Jacques H.
Nuermberger, Eric L.
[J]. PLOS MEDICINE, 2007, 4 (12) : 1931 - 1939
[33] Isoniazid pharmacokinetics in children treated for respiratory tuberculosis
Schaaf, HS
Parkin, DP
Seifart, HI
Werely, CJ
Hesseling, PB
van Helden, PD
Maritz, JS
Donald, PR
[J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2005, 90 (06) : 614 - 618
[34] A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, CK
Warrener, P
VanDevanter, DR
Sherman, DR
Arain, TM
Langhorne, MH
Anderson, SW
Towell, JA
Yuan, Y
McMurray, DN
Kreiswirth, BN
Barry, CE
Baker, WR
[J]. NATURE, 2000, 405 (6789) : 962 - 966
[35] Tangüis HG, 2000, INT J TUBERC LUNG D, V4, P55
[36] *TUB TRIALS CONS, 2008, TBTC STUDY 26 WEEKLY
[37] Diagnosis of sputum-scarce HIV-associated pulmonary tuberculosis in Lima, Peru
Vargas, D
Garcia, L
Gilman, RH
Evans, C
Ticona, E
Navincopa, M
Luo, RF
Caviedes, L
Hong, C
Escombe, R
Moore, DAJ
[J]. LANCET, 2005, 365 (9454) : 150 - 152
[38] *WHO, 2006, INT WORK GROUP PUBL
[39] Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis
Yee, D
Valiquette, C
Pelletier, M
Parisien, I
Rocher, I
Menzies, D
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (11) : 1472 - 1477
[40] Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial
Zar, Heather J.
Cotton, Mark F.
Strauss, Stanzi
Karpakis, Janine
Hussey, Gregory
Schaaf, Simon
Rabie, Helena
Lombard, Carl J.
[J]. BRITISH MEDICAL JOURNAL, 2007, 334 (7585): : 136 - 139

← 1 2 3 4 5 →